You Position: Home > Paper
Effects of statins combined with alirocumab on the structure and stability of coronary plaque in patients with coronary atherosclerotic heart disease with substandard blood lipid
( views:166, downloads:81 )
- Author:
- No author available
- Journal Title:
- China Medicine
- Issue:
- 11
- DOI:
- 10.3760/j.issn.1673-4777.2021.11.005
- Key Word:
- 冠心病(冠状动脉粥样硬化性心脏病);阿利西尤单抗;光学相干断层成像
Abstract： 目的 探讨他汀类药物联合阿利西尤单抗对血脂不达标冠心病(冠状动脉粥样硬化性心脏病)患者冠状动脉斑块结构和稳定性的影响.方法 回顾性分析首都医科大学附属北京安贞医院2018年1月至2020年3月收治的89例血脂不达标冠心病患者的临床资料.89例患者中继续原有他汀类药物治疗61例(对照组),在原有他汀治疗基础上联合阿利西尤单抗治疗28例(观察组).比较2组危险因素、冠心病二级预防药物使用情况和靶病变所在血管等基线资料,基线和12个月后随访时的血脂水平和光学相干断层成像(OCT)检查结果,记录随访期间死亡、心肌梗死、靶血管重建等临床终点事件和药物相关不良反应发生情况.结果 2组危险因素、冠心病二级预防药物使用情况和靶病变所在血管等基线资料和基线血脂水平、OCT检查指标水平比较差异均无统计学意义(均P>0.05).12个月后,观察组低密度脂蛋白胆固醇(LDL-C)的降低幅度,最小纤维帽厚度、最小管腔面积增加幅度和脂质弧度缩小幅度均高于对照组[12个月后随访时与基线的差值:(-1.89±0.61)mmol/L比(-0.75±0.66)mmol/L、(22.0±12.7)μm比(14.7±10.7)μm、(0.23±0.14)mm2比(0.15±0.13)mm2、(-16.8±11.4)°比(-10.1±9.9)°](均P<0.01).结论 在他汀类药物治疗基础上联合阿利西尤单抗治疗能进一步降低血脂不达标冠心病患者的LDL-C水平,改善冠状动脉斑块结构,提高其稳定性.
- [1]Falk,E.,Nakano,M.,Bentzon,J.F.,etc.Update on acute coronary syndromes: The pathologists' view[J].2013,34(10).
- [2]R, Virmani,F D, Kolodgie,A P, Burke,etc.Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions.[J].2000,20(5).
- [3]Johnson, Thomas W.,Raber, Lorenz,di Mario, Carlo,etc.Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Intervent[J].2019,40(31).
- [4]Fei Gao,Yu Jie Zhou.Contemporary Management and Attainment of Cholesterol Targets for Patients with Dyslipidemia in China.[J].2013,8(4).
- [5]VanDerSteen,A.F.W.,Terashima,M.,Sirbu,V.,etc.Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: A report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation[J].2012,59(12).
- [6]Michos, Erin D.,McEvoy, John W.,Blumenthal, Roger S..Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease[J].2019,381(16).
- [7]Yano, Hideki,Horinaka, Shigeo,Ishimitsu, Toshihiko.Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome[J].2020,75(3/4).
- [8]Shinke T,Shite J,Ogasawara D,etc.Feasibility of combined use of intravascular ultrasound radiofrequency data analysis and optical coherence tomography for detecting thin-cap fibroatheroma.[J].2008,29(9).
- [9]Schwartz, G. G.,Steg, P. G.,Szarek, M.,etc.Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome[J].2018,379(22).
- [10]Satoshi Honda,Scott M. Wasserman,Daisuke Shishikura,etc.Effect of Evolocumab on Coronary?Plaque Composition[J].2018,72(17).
- [11]Kini, Annapoorna S.,Vengrenyuk, Yuliya,Shameer, Khader,etc.Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment The YELLOW II Study[J].2017,69(6).